Collaborative, multinational clinical research, especially between developed and developing countries, has been the subject of controversy. Much of this attention has focused on the standard of care used in randomized trials. Much less discussed, but probably more important in terms of its impact on health, is the claim that, in order to avoid exploitation, interventions proven safe and effective through research in developing countries should be made "reasonably available" in those countries.